AB-3028 / ArsenalBio - LARVOL DELTA

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) (clinicaltrials.gov) - P1/2 | N=190 | Recruiting | Sponsor: Arsenal Biosciences, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) (clinicaltrials.gov) - P1/2 | N=190 | Not yet recruiting | Sponsor: Arsenal Biosciences, Inc.

New P1/2 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

AB-3028: Dual-targeting sequential AND logic gated CAR T cell for potential mCRPC therapeutic (SITC 2025) - "Importantly, we also describe the normal tissues that exhibit positivity for the antigens by RNA-seq and IHC. While the CAR target is an established target, pairing it with the PrimeR target significantly limits potential normal tissue exposure compared to targeting the CAR target alone, suggesting a potential enhanced safety profile.Conclusions These collective data support the development of AB-3028 for mCRPC."

CAR T-Cell Therapy • Castration-Resistant Prostate Cancer • Hematological Malignancies • Oncology • Prostate Cancer • TGFB1 • TGFBR2

Preclinical development of AB-3028, a logic-gated engineered CAR T cell product intended for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (SITC 2025) - "AB-3028 exhibited anti-tumor efficacy in the PC3 indication specific xenograft model and provided a survival benefit at doses 4-fold lower compared to a constitutive CAR including a dominant-negative TGF-β receptor (dnTGFβRII).Conclusions Preclinical data demonstrate that AB-3028 has selectivity for tumors, as well as multiple engineered features that enhance T cell fate and function in the tumor microenvironment. These results support the evaluation of AB-3028 in the clinic for the treatment of mCRPC."

CAR T-Cell Therapy • Metastases • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Hematological Malignancies • Oncology • Prostate Cancer • Solid Tumor • TGFB1 • TGFBR2

Preclinical development of AB-3028, a programmable circuit CAR T cell product intended for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (PCF 2025) - "Preclinical data demonstrate AB-3028's selectivity for mCRPC tumor targeting, and its modular features that enhance T cell fate and function in the tumor microenvironment. These results support clinical evaluation of AB-3028 for mCRPC treatment in a phase I/II clinical trial being initiated in early 2026."

CAR T-Cell Therapy • Metastases • Preclinical • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • TGFB1 • TGFBR2